Dublin, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Adeno-associated viruses (AAVs) are used in nearly a dozen FDA-approved therapies and more than 900 R&D projects to deliver therapeutic payloads to cells. Yet, large-scale AAV production is still a ...

Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced ...

Adeno-associated virus (AAV) is the most popular vector of choice for gene therapy because of its low immunogenicity and ability to infect numerous cells and tissue types. However, with hundreds of ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...

Virica Biotech ("Virica"), a cell enhancer company specializing in Viral Sensitizers (VSE ™) for viral vector manufacturing, today announced it is receiving advisory services and funding from the ...

ROCKVILLE, Md., May 8, 2026 /PRNewswire/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production ...